Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 6/2015

01-12-2015 | Review

The genetics of Leishmania virulence

Authors: Eugenia Bifeld, Joachim Clos

Published in: Medical Microbiology and Immunology | Issue 6/2015

Login to get access

Abstract

The ability of Leishmania parasites to infect and persist in the antigen-presenting cell population of their mammalian hosts is dependent on their ability to gain entry to their host and host cells, to survive the mammalian cell environment, and to suppress or evade the protective immune response mechanisms of their hosts. A multitude of genes and their products have been implicated in each of these virulence-enhancing strategies to date, and we present an overview of the nature and known function of such virulence genes.
Literature
1.
Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2(8):494–501PubMedCrossRef
2.
Desjeux P (2001) The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 95(3):239–243PubMedCrossRef
3.
Ben Salah AB, Ben Ismail R, Amri F, Chlif S, Ben Rzig F, Kharrat H, Hadhri H, Hassouna M, Dellagi K (2000) Investigation of the spread of human visceral leishmaniasis in central Tunisia. Trans R Soc Trop Med Hyg 94(4):382–386PubMedCrossRef
4.
Wolday D, Berhe N, Akuffo H, Desjeux P, Britton S (2001) Emerging Leishmania/HIV co-infection in Africa. Med Microbiol Immunol 190(1–2):65–67PubMedCrossRef
5.
6.
Desjeux P, Piot B, O’Neill K, Meert JP (2001) Co-infections of leishmania/HIV in south Europe. Med Trop: Revue du Corps de Sante Colonial 61(2):187–193
7.
Morales M, Watanabe R, Dacher M, Chafey P, Osorio y Fortéa J, Beverley S, Ommen G, Clos J, Hem S, Lenormand P, Rousselle J-C, Namane A, Spath G (2010) Phosphoproteome dynamics reveals heat shock protein complexes specific to the Leishmania infectious stage. Proc Natl Acad Sci USA 107(18):8381–8386PubMedCentralPubMedCrossRef
8.
9.
Brandau S, Dresel A, Clos J (1995) High constitutive levels of heat-shock proteins in human-pathogenic parasites of the genus Leishmania. Biochem J 310(Pt 1):225–232PubMedCentralPubMedCrossRef
10.
Argaman M, Aly R, Shapira M (1994) Expression of heat shock protein 83 in Leishmania is regulated post- transcriptionally. Mol Biochem Parasitol 64(1):95–110PubMedCrossRef
11.
12.
Ubeda JM, Legare D, Raymond F, Ouameur AA, Boisvert S, Rigault P, Corbeil J, Tremblay MJ, Olivier M, Papadopoulou B, Ouellette M (2008) Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy. Genome Biol 9(7):R115. doi:10.​1186/​gb-2008-9-7-r115 PubMedCentralPubMedCrossRef
13.
Pimenta PFP, Turco SJ, McConville MJ, Lawyer PG, Perkins PV, Sacks DL (1992) Stage-specific adhesion of Leishmania promastigotes to the sandfly midgut. Science 256:1812–1815PubMedCrossRef
14.
Sacks DL, Perkins PV (1984) Identification of an infective stage of Leishmania promastigotes. Science 223(4643):1417–1419PubMedCrossRef
15.
Saraiva EM, Pimenta PF, Brodin TN, Rowton E, Modi GB, Sacks DL (1995) Changes in lipophosphoglycan and gene expression associated with the development of Leishmania major in Phlebotomus papatasi. Parasitology 111(Pt 3):275–287PubMedCrossRef
16.
Zilberstein D, Shapira M (1994) The role of pH and temperature in the development of Leishmania parasites. Annu Rev Microbiol 48:449–470PubMedCrossRef
17.
Croft SL, Seifert K, Yardley V (2006) Current scenario of drug development for leishmaniasis. Indian J Med Res 123(3):399–410PubMed
18.
Sundar S, Rai M (2005) Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6(16):2821–2829PubMedCrossRef
19.
Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW (2008) New treatment approach in indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 47(8):1000–1006. doi:10.​1086/​591972 PubMedCrossRef
20.
21.
22.
23.
Riera C, Fisa R, Udina M, Gallego M, Portus M (2004) Detection of Leishmania infantum cryptic infection in asymptomatic blood donors living in an endemic area (Eivissa, Balearic Islands, Spain) by different diagnostic methods. Trans R Soc Trop Med Hyg 98(2):102–110PubMedCrossRef
24.
D’Oliveira Junior A, Costa SR, Barbosa AB, MdlG Orge, Carvalho EM (1997) Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis. Mem Inst Oswaldo Cruz 92(1):15–20PubMedCrossRef
25.
Pampiglione S, Manson-Bahr PE, Giungi F, Giunti G, Parenti A, Trotti GC (1974) Studies on Mediterranean leishmaniasis. 2. Asymptomatic cases of visceral leishmaniasis. Trans R Soc Trop Med Hyg 68(6):447–453PubMedCrossRef
26.
Caldas AJ, Costa JM, Silva AA, Vinhas V, Barral A (2002) Risk factors associated with asymptomatic infection by Leishmania chagasi in north-east Brazil. Trans R Soc Trop Med Hyg 96(1):21–28PubMedCrossRef
27.
28.
29.
Berman JD, Neva FA (1981) Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg 30(2):318–321PubMed
30.
Sacks DL, Barral A, Neva FA (1983) Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. Am J Trop Med Hyg 32(2):300–304PubMed
31.
Zhang WW, Matlashewski G (1997) Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci USA 94(16):8807–8811PubMedCentralPubMedCrossRef
32.
33.
34.
Hombach A, Ommen G, MacDonald A, Clos J (2014) A small heat shock protein is essential for thermotolerance and intracellular survival of Leishmania donovani. J Cell Sci 127:4762–4773PubMedCentralPubMedCrossRef
35.
Cardenas D, Carter PM, Nation CS, Pizarro JC, Guidry J, Aiyar A, Kelly BL (2015) LACK, a RACK1 ortholog, facilitates cytochrome c oxidase subunit expression to promote Leishmania major fitness. Mol Microbiol 96(1):95–109. doi:10.​1111/​mmi.​12924 PubMedCrossRef
36.
37.
Goyal N, Roy U, Rastogi AK (1996) Relative resistance of promastigotes of a virulent and an avirulent strain of Leishmania donovani to hydrogen peroxide. Free Radic Biol Med 21(5):683–689PubMedCrossRef
38.
Dumas C, Ouellette M, Tovar J, Cunningham ML, Fairlamb AH, Tamar S, Olivier M, Papadopoulou B (1997) Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J 16(10):2590–2598PubMedCentralPubMedCrossRef
39.
Acestor N, Masina S, Ives A, Walker J, Saravia NG, Fasel N (2006) Resistance to oxidative stress is associated with metastasis in mucocutaneous leishmaniasis. J Infect Dis 194(8):1160–1167. doi:10.​1086/​507646 PubMedCrossRef
40.
Brittingham A, Morrison CJ, McMaster WR, McGwire BS, Chang KP, Mosser DM (1995) Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. J Immunol 155(6):3102–3111PubMed
41.
McGwire B, Chang KP (1994) Genetic rescue of surface metalloproteinase (gp63)-deficiency in Leishmania amazonensis variants increases their infection of macrophages at the early phase. Mol Biochem Parasitol 66(2):345–347PubMedCrossRef
42.
Liu X, Chang KP (1992) Extrachromosomal genetic complementation of surface metalloproteinase (gp63)-deficient Leishmania increases their binding to macrophages. Proc Natl Acad Sci USA 89(11):4991–4995PubMedCentralPubMedCrossRef
43.
Brittingham A, Chen G, McGwire BS, Chang KP, Mosser DM (1999) Interaction of Leishmania gp63 with cellular receptors for fibronectin. Infect Immun 67(9):4477–4484PubMedCentralPubMed
44.
45.
Sacks DL, Modi G, Rowton E, Spath G, Epstein L, Turco SJ, Beverley SM (2000) The role of phosphoglycans in Leishmania-sand fly interactions. Proc Natl Acad Sci USA 97(1):406–411PubMedCentralPubMedCrossRef
46.
Kamhawi S, Ramalho-Ortigao M, Pham VM, Kumar S, Lawyer PG, Turco SJ, Barillas-Mury C, Sacks DL, Valenzuela JG (2004) A role for insect galectins in parasite survival. Cell 119(3):329–341PubMedCrossRef
47.
Sacks DL (2001) Leishmania-sand fly interactions controlling species-specific vector competence. Cell Microbiol 3(4):189–196PubMedCrossRef
48.
Grimm F, Jenni L (1993) Human serum resistant promastigotes of Leishmania infantum in the midgut of Phlebotomus perniciosus. Acta Trop 52(4):267–273PubMedCrossRef
49.
Puentes SM, Da Silva RP, Sacks DL, Hammer CH, Joiner KA (1990) Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9. J Immunol 145(12):4311–4316PubMed
50.
51.
52.
Spath GF, Epstein L, Leader B, Singer SM, Avila HA, Turco SJ, Beverley SM (2000) Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc Natl Acad Sci USA 97(16):9258–9263PubMedCentralPubMedCrossRef
53.
54.
55.
Kelleher M, Bacic A, Handman E (1992) Identification of a macrophage-binding determinant on lipophosphoglycan from Leishmania major promastigotes. Proc Natl Acad Sci USA 89(1):6–10PubMedCentralPubMedCrossRef
56.
Puentes SM, Sacks DL, da Silva RP, Joiner KA (1988) Complement binding by two developmental stages of Leishmania major promastigotes varying in expression of a surface lipophosphoglycan. J Exp Med 167(3):887–902PubMedCrossRef
57.
58.
Dermine JF, Scianimanico S, Prive C, Descoteaux A, Desjardins M (2000) Leishmania promastigotes require lipophosphoglycan to actively modulate the fusion properties of phagosomes at an early step of phagocytosis. Cell Microbiol 2(2):115–126PubMedCrossRef
59.
60.
61.
62.
Gueirard P, Laplante A, Rondeau C, Milon G, Desjardins M (2008) Trafficking of Leishmania donovani promastigotes in non-lytic compartments in neutrophils enables the subsequent transfer of parasites to macrophages. Cell Microbiol 10(1):100–111. doi:10.​1111/​j.​1462-5822.​2007.​01018.​x PubMed
63.
64.
65.
van Zandbergen G, Bollinger A, Wenzel A, Kamhawi S, Voll R, Klinger M, Muller A, Holscher C, Herrmann M, Sacks D, Solbach W, Laskay T (2006) Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum. Proc Natl Acad Sci USA 103(37):13837–13842. doi:10.​1073/​pnas.​0600843103 PubMedCentralPubMedCrossRef
66.
Naderer T, Vince JE, McConville MJ (2004) Surface determinants of Leishmania parasites and their role in infectivity in the mammalian host. Curr Mol Med 4(6):649–665PubMedCrossRef
67.
Russo DM, Turco SJ, Burns JM Jr, Reed SG (1992) Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins. J Immunol 148(1):202–207PubMed
68.
Jardim A, Funk V, Caprioli RM, Olafson RW (1995) Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochem J 305(Pt 1):307–313PubMedCentralPubMedCrossRef
69.
Jardim A, Tolson DL, Turco SJ, Pearson TW, Olafson RW (1991) The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex. J Immunol 147(10):3538–3544PubMed
70.
Stebeck CE, Beecroft RP, Singh BN, Jardim A, Olafson RW, Tuckey C, Prenevost KD, Pearson TW (1995) Kinetoplastid membrane protein-11 (KMP-11) is differentially expressed during the life cycle of African trypanosomes and is found in a wide variety of kinetoplastid parasites. Mol Biochem Parasitol 71(1):1–13PubMedCrossRef
71.
Matos DC, Faccioli LA, Cysne-Finkelstein L, Luca PM, Corte-Real S, Armoa GR, Lemes EM, Decote-Ricardo D, Mendonca SC (2010) Kinetoplastid membrane protein-11 is present in promastigotes and amastigotes of Leishmania amazonensis and its surface expression increases during metacyclogenesis. Mem Inst Oswaldo Cruz 105(3):341–347PubMedCrossRef
72.
73.
74.
Abebe T, Takele Y, Weldegebreal T, Cloke T, Closs E, Corset C, Hailu A, Hailu W, Sisay Y, Corware K, Corset M, Modolell M, Munder M, Tacchini-Cottier F, Muller I, Kropf P (2013) Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopia. PLoS Negl Trop Dis 7(3):e2134. doi:10.​1371/​journal.​pntd.​0002134 PubMedCentralPubMedCrossRef
75.
76.
Roberts SC, Tancer MJ, Polinsky MR, Gibson KM, Heby O, Ullman B (2004) Arginase plays a pivotal role in polyamine precursor metabolism in Leishmania. Characterization of gene deletion mutants. J Biol Chem 279(22):23668–23678. doi:10.​1074/​jbc.​M402042200 PubMedCrossRef
77.
Iniesta V, Gomez-Nieto LC, Corraliza I (2001) The inhibition of arginase by N(omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J Exp Med 193(6):777–784PubMedCentralPubMedCrossRef
78.
Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S (2005) Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174(11):7160–7171PubMedCrossRef
79.
Joshi PB, Kelly BL, Kamhawi S, Sacks DL, McMaster WR (2002) Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol Biochem Parasitol 120(1):33–40PubMedCrossRef
80.
81.
82.
83.
Gomez MA, Contreras I, Halle M, Tremblay ML, McMaster RW, Olivier M (2009) Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases. Sci Signal 2 (90):ra58. doi:10.​1126/​scisignal.​2000213
84.
Halle M, Gomez MA, Stuible M, Shimizu H, McMaster WR, Olivier M, Tremblay ML (2009) The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation. J Biol Chem 284(11):6893–6908. doi:10.​1074/​jbc.​M805861200 PubMedCentralPubMedCrossRef
85.
Corradin S, Ransijn A, Corradin G, Roggero MA, Schmitz AA, Schneider P, Mauel J, Vergeres G (1999) MARCKS-related protein (MRP) is a substrate for the Leishmania major surface protease leishmanolysin (gp63). J Biol Chem 274(36):25411–25418PubMedCrossRef
86.
Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49(11):1939–1945PubMedCrossRef
87.
Holm A, Tejle K, Gunnarsson T, Magnusson KE, Descoteaux A, Rasmusson B (2003) Role of protein kinase C alpha for uptake of unopsonized prey and phagosomal maturation in macrophages. Biochem Biophys Res Commun 302(4):653–658PubMedCrossRef
88.
89.
90.
Gregory DJ, Godbout M, Contreras I, Forget G, Olivier M (2008) A novel form of NF-kappaB is induced by Leishmania infection: involvement in macrophage gene expression. Eur J Immunol 38(4):1071–1081. doi:10.​1002/​eji.​200737586 PubMedCrossRef
91.
Silverman JM, Clos J, Horakova E, Wang AY, Wiesgigl M, Kelly I, Lynn MA, McMaster WR, Foster LJ, Levings MK, Reiner NE (2010) Leishmania exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells. J Immunol 185(9):5011–5022. doi:10.​4049/​jimmunol.​1000541 PubMedCrossRef
92.
Matheoud D, Moradin N, Bellemare-Pelletier A, Shio MT, Hong WJ, Olivier M, Gagnon E, Desjardins M, Descoteaux A (2013) Leishmania evades host immunity by inhibiting antigen cross-presentation through direct cleavage of the SNARE VAMP8. Cell Host Microbe 14(1):15–25. doi:10.​1016/​j.​chom.​2013.​06.​003 PubMedCrossRef
93.
94.
Mottram JC, Frame MJ, Brooks DR, Tetley L, Hutchison JE, Souza AE, Coombs GH (1997) The multiple cpb cysteine proteinase genes of Leishmania mexicana encode isoenzymes that differ in their stage regulation and substrate preferences. J Biol Chem 272(22):14285–14293PubMedCrossRef
95.
Duboise SM, Vannier-Santos MA, Costa-Pinto D, Rivas L, Pan AA, Traub-Cseko Y, De Souza W, McMahon-Pratt D (1994) The biosynthesis, processing, and immunolocalization of Leishmania pifanoi amastigote cysteine proteinases. Mol Biochem Parasitol 68(1):119–132PubMedCrossRef
96.
Pupkis MF, Tetley L, Coombs GH (1986) Leishmania mexicana: amastigote hydrolases in unusual lysosomes. Exp Parasitol 62(1):29–39PubMedCrossRef
97.
Silverman JM, Clos J, de’Oliveira CC, Shirvani O, Fang Y, Wang C, Foster LJ, Reiner NE (2010) An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages. J Cell Sci 123(Pt 6):842–852. doi:10.​1242/​jcs.​056465 PubMedCrossRef
98.
Mottram JC, Souza AE, Hutchison JE, Carter R, Frame MJ, Coombs GH (1996) Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc Natl Acad Sci USA 93(12):6008–6013PubMedCentralPubMedCrossRef
99.
Frame MJ, Mottram JC, Coombs GH (2000) Analysis of the roles of cysteine proteinases of Leishmania mexicana in the host-parasite interaction. Parasitology 121(Pt 4):367–377PubMedCrossRef
100.
Alexander J, Coombs GH, Mottram JC (1998) Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 161(12):6794–6801PubMed
101.
Pollock KG, McNeil KS, Mottram JC, Lyons RE, Brewer JM, Scott P, Coombs GH, Alexander J (2003) The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses. J Immunol 170(4):1746–1753PubMedCrossRef
102.
De Souza Leao S, Lang T, Prina E, Hellio R, Antoine JC (1995) Intracellular Leishmania amazonensis amastigotes internalize and degrade MHC class II molecules of their host cells. J Cell Sci 108(Pt 10):3219–3231
103.
Denise H, McNeil K, Brooks DR, Alexander J, Coombs GH, Mottram JC (2003) Expression of multiple CPB genes encoding cysteine proteases is required for Leishmania mexicana virulence in vivo. Infect Immun 71(6):3190–3195PubMedCentralPubMedCrossRef
104.
Buxbaum LU, Denise H, Coombs GH, Alexander J, Mottram JC, Scott P (2003) Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity. J Immunol 171(7):3711–3717PubMedCrossRef
105.
Launois P, Maillard I, Pingel S, Swihart KG, Xenarios I, Acha-Orbea H, Diggelmann H, Locksley RM, MacDonald HR, Louis JA (1997) IL-4 rapidly produced by V beta 4 V alpha 8 CD4 + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6(5):541–549PubMedCrossRef
106.
107.
108.
109.
Selzer PM, Chen X, Chan VJ, Cheng M, Kenyon GL, Kuntz ID, Sakanari JA, Cohen FE, McKerrow JH (1997) Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp Parasitol 87(3):212–221. doi:10.​1006/​expr.​1997.​4220 PubMedCrossRef
110.
Somanna A, Mundodi V, Gedamu L (2002) Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex. Evidence for the activation of latent transforming growth factor beta. J Biol Chem 277(28):25305–25312PubMedCrossRef
111.
112.
113.
Hunter KW, Cook CL, Hayunga EG (1984) Leishmanial differentiation in vitro: induction of heat shock proteins. Biochem Biophys Res Commun 125(2):755–760PubMedCrossRef
114.
van der Ploeg LHT, Giannini SH, Cantor CR (1985) Heat shock genes: regulatory role for differentiation in parasitic protozoa. Science 228:1443–1446PubMedCrossRef
115.
Hübel A, Krobitsch S, Horauf A, Clos J (1997) Leishmania major Hsp100 is required chiefly in the mammalian stage of the parasite. Mol Cell Biol 17(10):5987–5995PubMedCentralPubMedCrossRef
116.
Hübel A, Brandau S, Dresel A, Clos J (1995) A member of the ClpB family of stress proteins is expressed during heat shock in Leishmania spp. Mol Biochem Parasitol 70(1–2):107–118PubMedCrossRef
117.
Yau W-L, Pescher P, Macdonald A, Zander D, Retzlaff S, Blisnick T, Rotureau B, Bastin P, Clos J, Späth G (2014) Cyclophilin 40-deficient Leishmania donovani fail to undergo stress-induced development of the infectious metacyclic stage. Cell Microbiol 93:80–97. doi:10.​1111/​mmi.​12639
118.
119.
Krobitsch S, Brandau S, Hoyer C, Schmetz C, Hübel A, Clos J (1998) Leishmania donovani heat shock protein 100: characterization and function in amastigote stage differentiation. J Biol Chem 273:6488–6494PubMedCrossRef
120.
121.
Nandan D, Yi T, Lopez M, Lai C, Reiner NE (2002) Leishmania EF-1alpha activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation. J Biol Chem 277(51):50190–50197. doi:10.​1074/​jbc.​M209210200 PubMedCrossRef
122.
123.
Proudfoot L, Nikolaev AV, Feng GJ, Wei WQ, Ferguson MA, Brimacombe JS, Liew FY (1996) Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages. Proc Natl Acad Sci USA 93(20):10984–10989PubMedCentralPubMedCrossRef
124.
Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S (1990) Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144(12):4794–4797PubMed
125.
126.
Chan ED, Riches DW (2001) IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 280(3):C441–C450PubMed
127.
Lehtonen A, Matikainen S, Julkunen I (1997) Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J Immunol 159(2):794–803PubMed
128.
Nandan D, Lo R, Reiner NE (1999) Activation of phosphotyrosine phosphatase activity attenuates mitogen-activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with Leishmania donovani. Infect Immun 67(8):4055–4063PubMedCentralPubMed
129.
130.
Bhardwaj N, Rosas LE, Lafuse WP, Satoskar AR (2005) Leishmania inhibits STAT1-mediated IFN-gamma signaling in macrophages: increased tyrosine phosphorylation of dominant negative STAT1beta by Leishmania mexicana. Int J Parasitol 35(1):75–82. doi:10.​1016/​j.​ijpara.​2004.​10.​018 PubMedCrossRef
131.
132.
133.
134.
135.
Olivier M, Romero-Gallo BJ, Matte C, Blanchette J, Posner BI, Tremblay MJ, Faure R (1998) Modulation of interferon-gamma-induced macrophage activation by phosphotyrosine phosphatases inhibition. Effect on murine leishmaniasis progression. J Biol Chem 273(22):13944–13949PubMedCrossRef
136.
Reiling L, Chrobak M, Schmetz C, Clos J (2010) Overexpression of a single Leishmania major gene is sufficient to enhance parasite infectivity in vivo and in vitro. Mol Microbiol 76(5):1175–1190PubMedCentralPubMedCrossRef
137.
138.
139.
Silverman JM, Chan SK, Robinson DP, Dwyer DM, Nandan D, Foster LJ, Reiner NE (2008) Proteomic analysis of the secretome of Leishmania donovani. Genome Biol 9(2):R35PubMedCentralPubMedCrossRef
140.
141.
Doyle PS, Engel JC, Pimenta PF, da Silva PP, Dwyer DM (1991) Leishmania donovani: long-term culture of axenic amastigotes at 37 degrees C. Exp Parasitol 73(3):326–334PubMedCrossRef
142.
Lovelace JK, Dwyer DM, Gottlieb M (1986) Purification and characterization of the extracellular acid phosphatase of Leishmania donovani. Mol Biochem Parasitol 20(3):243–251PubMedCrossRef
143.
Gottlieb M, Dwyer DM (1982) Identification and partial characterization of an extracellular acid phosphatase activity of Leishmania donovani promastigotes. Mol Cell Biol 2(1):76–81PubMedCentralPubMedCrossRef
144.
145.
Ellis SL, Shakarian AM, Dwyer DM (1998) Leishmania: amastigotes synthesize conserved secretory acid phosphatases during human infection. Exp Parasitol 89(2):161–168PubMedCrossRef
146.
Remaley AT, Das S, Campbell PI, LaRocca GM, Pope MT, Glew RH (1985) Characterization of Leishmania donovani acid phosphatases. J Biol Chem 260(2):880–886PubMed
147.
Menz B, Winter G, Ilg T, Lottspeich F, Overath P (1991) Purification and characterization of a membrane-bound acid phosphatase of Leishmania mexicana. Mol Biochem Parasitol 47(1):101–108PubMedCrossRef
148.
Remaley AT, Glew RH, Kuhns DB, Basford RE, Waggoner AS, Ernst LA, Pope M (1985) Leishmania donovani: surface membrane acid phosphatase blocks neutrophil oxidative metabolite production. Exp Parasitol 60(3):331–341PubMedCrossRef
149.
Katakura K, Kobayashi A (1988) Acid phosphatase activity of virulent and avirulent clones of Leishmania donovani promastigotes. Infect Immun 56(11):2856–2860PubMedCentralPubMed
150.
Singla N, Khuller GK, Vinayak VK (1992) Acid phosphatase activity of promastigotes of Leishmania donovani: a marker of virulence. FEMS Microbiol Lett 73(3):221–225PubMedCrossRef
151.
152.
153.
154.
Carrera L, Gazzinelli RT, Badolato R, Hieny S, Muller W, Kuhn R, Sacks DL (1996) Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 183(2):515–526PubMedCrossRef
155.
Reiner NE, Ng W, Wilson CB, McMaster WR, Burchett SK (1990) Modulation of in vitro monocyte cytokine responses to Leishmania donovani. Interferon-gamma prevents parasite-induced inhibition of interleukin 1 production and primes monocytes to respond to Leishmania by producing both tumor necrosis factor-alpha and interleukin 1. J Clin Investig 85(6):1914–1924. doi:10.​1172/​JCI114654 PubMedCentralPubMedCrossRef
156.
Reiner NE (1987) Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani. J Immunol 138(6):1919–1925PubMed
157.
Reiner NE, Ng W, McMaster WR (1987) Parasite-accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. J Immunol 138(6):1926–1932PubMed
158.
Chang KP, Reed SG, McGwire BS, Soong L (2003) Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop 85(3):375–390PubMedCrossRef
159.
Burns JM Jr, Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG (1993) Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci USA 90(2):775–779PubMedCentralPubMedCrossRef
160.
Singh S, Gilman-Sachs A, Chang KP, Reed SG (1995) Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitolo 81(6):1000–1003CrossRef
161.
Zhang WW, Mendez S, Ghosh A, Myler P, Ivens A, Clos J, Sacks DL, Matlashewski G (2003) Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. J Biol Chem 278(37):35508–35515. doi:10.​1074/​jbc.​M305030200 PubMedCrossRef
162.
Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, Matlashewski G (1997) Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol 4(5):530–535PubMedCentralPubMed
163.
Carvalho LP, Passos S, Dutra WO, Soto M, Alonso C, Gollob KJ, Carvalho EM, Ribeiro de Jesus A (2005) Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients. Scand J Immunol 61(4):337–342. doi:10.​1111/​j.​1365-3083.​2005.​01581.​x PubMedCrossRef
164.
Ramirez JR, Berberich C, Jaramillo A, Alonso C, Velez IV (1998) Molecular and antigenic characterization of the Leishmania (Viannia) panamensis kinetoplastid membrane protein-11. Mem Inst Oswaldo Cruz 93(2):247–254PubMedCrossRef
165.
Carmelo E, Martinez E, Gonzalez AC, Pinero JE, Patarroyo ME, Del Castillo A, Valladares B (2002) Antigenicity of Leishmania braziliensis histone H1 during cutaneous leishmaniasis: localization of antigenic determinants. Clin Diagn Lab Immunol 9(4):808–811PubMedCentralPubMed
166.
Maalej IA, Chenik M, Louzir H, Ben Salah A, Bahloul C, Amri F, Dellagi K (2003) Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. Am J Trop Med Hyg 68(3):312–320PubMed
167.
Skeiky YA, Benson DR, Guderian JA, Whittle JA, Bacelar O, Carvalho EM, Reed SG (1995) Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans. Infect Immun 63(10):4105–4114PubMedCentralPubMed
168.
Webb JR, Campos-Neto A, Skeiky YA, Reed SG (1997) Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major [In Process Citation]. Mol Biochem Parasitol 89(2):179–193PubMedCrossRef
169.
Pfeffer K, Schoel B, Gulle H, Moll H, Kromer S, Kaufmann SH, Wagner H (1991) Analysis of primary T cell responses to intact and fractionated microbial pathogens. Curr Top Microbiol Immunol 173:173–178PubMed
170.
Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L (2007) Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine 25(21):4159–4169PubMedCrossRef
171.
172.
McCall LI, Zhang WW, Dejgaard K, Atayde VD, Mazur A, Ranasinghe S, Liu J, Olivier M, Nilsson T, Matlashewski G (2015) Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis. J Proteome Res 14(2):1033–1059. doi:10.​1021/​pr5010604 PubMedCrossRef
173.
Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM (2004) Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect Immun 72(6):3622–3627PubMedCentralPubMedCrossRef
174.
175.
Leprohon P, Legare D, Raymond F, Madore E, Hardiman G, Corbeil J, Ouellette M (2009) Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res 37(5):1387–1399. doi:10.​1093/​nar/​gkn1069 PubMedCentralPubMedCrossRef
Metadata
Title
The genetics of Leishmania virulence
Authors
Eugenia Bifeld
Joachim Clos
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 6/2015
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-015-0422-1

Other articles of this Issue 6/2015

Medical Microbiology and Immunology 6/2015 Go to the issue

Original Investigation

Prevalence of Mycobacterium avium subsp. paratuberculosis and Escherichia coli in blood samples from patients with inflammatory bowel disease

Original Investigation

Activated matrix metalloproteinase-8 in saliva as diagnostic test for periodontal disease? A case–control study

Original Investigation

Increased viability but decreased culturability of Mycobacterium avium subsp. paratuberculosis in macrophages from inflammatory bowel disease patients under Infliximab treatment

Original Investigation

ExoU-induced redox imbalance and oxidative stress in airway epithelial cells during Pseudomonas aeruginosa pneumosepsis

Original Investigation

Early identification of renal transplant recipients with high risk of polyomavirus-associated nephropathy

Original Investigation

The anti-obesity drug orlistat reveals anti-viral activity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits